Boehringer Ingelheim Venture Fund co-led the oncology drug developer's series A round with Delos Capital and Xeraya Capital.

US-based cancer immunotherapy developer OncoMyx Therapeutics closed a $25m series A round yesterday co-led by Boehringer Ingelheim Venture Fund (BIVF), the corporate venturing vehicle for pharmaceutical firm Boehringer Ingelheim. BIVF co-led the round with private equity firm Delos Capital and life sciences investment vehicle Xeraya Capital, while Korea Investment Partners, City Hill Ventures and Madison…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.